Join Julie Cox for Aesthetic Medicine North’s opening lecture on The Upper Third
Independent Nurse Prescriber Julie Cox will be opening the clinical conference at Aesthetic Medicine North with a session examining techniques for rejuvenating the upper third using AbobotulinumtoxinA.
Julie, who is training manager for Galderma and has more than 16 years of aesthetics experience, having been heavily involved in setting validation standards in the industry, coaches and teaches clinicians of all levels in treatment with botulinum toxin.
Her session will include a 40 minute presentation on Azzalure* (AbobotulinumtoxinA), giving an overview of the science, indications, safety and relevant anatomical structures as well as a 20 minute interactive session including a video demonstration of a toxin treatment of the glabellar and lateral canthal lines.
This session will be chaired by Dr Daniel Sister.
Conference sessions can be booked for £12.50 + VAT each.
IMPORTANT INFORMATION: Please note that the clinical conference on Saturday June 29 is only open to those with a valid registration to the General Medical Council, Nursing Midwifery Council or General Dental Council due to the presence of prescription only medications and medical procedures. Aesthetic Medicine reserves the right to refuse entry to anyone not able to provide details of a valid registration, anyone attempting to book using someone else’s registration number or those falsely providing details of a registration. All details will be checked before the event and no refunds will be available to anyone attempting to access the clinical programme without a valid registration.
*Azzalure Prescribing Information (UK & IRE)
Presentation:Botulinum toxin type A (Clostridium botulinumtoxin A haemagglutinin complex) 125 Speywood units of reconstituted solution (powder for solution for injection)
Indications:Temporary improvement in appearance of moderate to severe:
- Glabellar lines seen at maximum frown, and/or
- lateral canthal lines (crow’s feet lines) seen at maximum smile in adult patients under 65 years, when severity of these lines has an important psychological impact on the patient.
Dosage & Administration:Azzalure should only be administered by physicians with appropriate qualifications and expertise in this treatment and having the required equipment. Botulinum toxin units are different depending on the medicinal products.Speywood units are specific to this preparation and are not interchangeable with other botulinum toxins.Reconstitute prior to injection. Intramuscular injections should be performed using a sterile suitable gauge needle.
Glabellar lines: recommended dose is 50 Speywood units divided equally into 5 injection sites, 10 Speywood units to be administered intramuscularly, at right angles to the skin; 2 injections into each corrugatormuscle and one into the procerusmuscle near the nasofrontal angle.
Lateral canthal lines: recommended dose per side is 30 Speywood units divided into 3 injection sites; 10 Speywood units to be administered intramuscularly into each injection point, injected lateral (20 - 30° angle) to the skin and very superficial. All injection points should be at the external part of the orbicularis oculi muscle and sufficiently far from the orbital rim (approximately 1 - 2 cm); (See summary of product characteristics for full technique).
Treatment interval should not be more frequent than every three months. The efficacy and safety of repeat injections of Azzalure has been evaluated in Glabellar lines up to 24 months and up to 8 repeat treatment cycles and for Lateral Canthal lines up to 12 months and up to 5 repeat treatment cycles. Not recommended for use in individuals under 18 years of age.
Contraindications: In individuals with hypersensitivity to botulinum toxin A or to any of the excipients. In the presence of infection at the proposed injection sites,myasthenia gravis, Eaton Lambert Syndrome or amyotrophic lateral sclerosis.
Special warnings and precautions for use: Care should be taken to ensure that Azzalure is not injected into a blood vessel. Use with caution in patients with a risk of, or clinical evidence of, marked defective neuro-muscular transmission, in the presence of inflammation at the proposed injection site(s) or when the targeted muscle shows excessive weakness or atrophy. Patients treated with therapeutic doses may experience exaggerated muscle weakness. Not recommended in patients with history of dysphagia, aspiration or with prolonged bleeding time. Seek immediate medical care if swallowing, speech or respiratory difficulties arise.
Facial asymmetry, ptosis, excessive dermatochalasis, scarring and any alterations to facial anatomy, as a result of previous surgical interventions should be taken into consideration prior to injection.
Injections at more frequent intervals/higher doses can increase the risk of antibody formation. Avoid administering different botulinum neurotoxins during the course of treatment with Azzalure.
To be used for one single patient treatment only during a single session.There is a potential risk of localised muscle weakness or visual disturbances linked with the use of this medicinal product which may temporarily impair the ability to drive or operate machinery.
Interactions:Concomitant treatment with aminoglycosides or other agents interfering with neuromuscular transmission (e.g. curare-like agents) may potentiate effect of botulinum toxin.
Pregnancy, Lactation & Fertility:Not to be used during pregnancy or lactation. There are no clinical data from the use of Azzalure on fertility. There is no evidence of direct effect of Azzalure on fertility in animal studies
Side Effects:Most frequently occurring related reactions are headache and injection site reactions for glabellar lines and; headache, injection site reactions and eyelid oedema for lateral canthal lines. Generally treatment/injection technique related reactions occur within first week following injection and are transient. Undesirable effects may be related to the active substance, the injection procedure, or a combination of both.
For glabellar lines: Very Common (≥ 1/10): Headache, Injection site reactions (e.g. erythema, oedema, irritation, rash, pruritus, paraesthesia, pain, discomfort, stinging and haematoma). Common (≥ 1/100 to < 1/10): Temporary facial paresis (due to temporary paresis of facial muscles proximal to injection sites, predominantly describes brow paresis), Asthenopia, Eyelid ptosis, Eyelid oedema, Lacrimation increase, Dry eye, Muscle twitching (twitching of muscles around the eyes). Uncommon (≥ 1/1,000 to <1/100): Dizziness, Visual impairment, Vision blurred, Diplopia, Pruritus, Rash, Hypersensitivity, Eye movement disorder. Rare (≥ 1/10,000 to < 1/1,000): Urticaria.
For lateral canthal lines: Common (≥ 1/100 to < 1/10): Headache, Temporary facial paresis (due to temporary paresis of facial muscles proximal to injection sites), Eyelid ptosis, Eyelid oedema and Injection site disorders (e.g. haematoma, pruritus and oedema). Uncommon (≥ 1/1,000 to <1/100): Dry eye.
Adverse reactions resulting from distribution of the effects of the toxin to sites remote from the site of injection have been very rarely reported with botulinum toxin (excessive muscle weakness, dysphagia, aspiration pneumonia with fatal outcome in some cases). Prescribers should consult the summary of product characteristics in relation to other side effects.
Packaging Quantities & Cost:UK 1 Vial Pack (1 x 125u) £64.00 (RRP), 2 Vial Pack (2 x 125u) £128.00 (RRP), IRE 1 Vial Pack (1 x 125u) €93.50,2 Vial Pack (2 x 125u) €187.05(RRP)
Marketing Authorisation Number: PL 06958/0031 (UK), PA 1613/001/001 (IRE)
Legal Category: POM
Further Information is Available From: Galderma (UK) Limited, Meridien House, 69-71 Clarendon Road, Watford, Herts. WD17 1DS, UK. Tel: +44 (0) 1923 208950 Fax: +44 (0) 1923 208998
Date of Revision: September 2018
Adverse events should be reported.
For the UK, Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.
Adverse events should also be reported to Galderma (UK) Ltd.
